Investors Back iOmx’s Focus On Tumor Immune Evasion
Developing Anti-Immune Evasion Platform
Executive Summary
The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022
You may also be interested in...
Can Sarepta Beat Pfizer To A Duchenne Gene Therapy Breakthrough?
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.
CRISPR Therapeutics Moves Into Off-The-Shelf CAR-T Lead, But Durability Test Awaits
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.
New GSK To Leave Flagship HQ After Consumer Health Split
Company follows US office downsizing with similar plans for its global headquarters, once consumer health spin-out is complete in 2022.